Showing posts from September, 2017

Misconduct in the Pharmaceutical trade - GlaxoSmithKline

Misconduct in the Pharmaceutical trade - GlaxoSmithKline - $9,380,000,000 (Yes, 9,38 Billion in fines and settlements)
This was the first time during my research that I was nauseated and shocked to the point of feeling punch-drunk as a result of the facts. It is incredible that a company that has accrued so much in criminal and civil fines and penalties is still operating. Excepting China, not one single employee of GlaxoSmithKline has been charged relating to the information below. You will note that I did not include the customary origin and history of this company, as the content of malfeasance is already sizeable. So let’s get to it.
1. 1984 - The U.S. Food and Drug Administration (FDA) brings charges under the criminal provisions of federal drug laws against what was then SmithKline Beckman, alleging that the company failed to warn regulators and the public about potentially lethal side effects associated with its blood pressure medication Selacryn. This drug was linked to 36 de…

Corruption in the Pharmaceutical Trade - BAYER AG

Corruption in the Pharmaceutical Trade
BAYER AGAs an opener to this article that describes very directly what the corporate world of pharmaceuticals is about, I would like to quote Marijn Dekkers, CEO of Bayer AG, December 3, 2013 – “We did not develop this medicine for Indians. We developed it for Western patients who can afford it.” The original Businessweek article has been removed from the internet, including its internet cache and the video that was on,

Bayer AG can trace its roots back to August 1863 with the creation of “Friedr.Bayer et comp”, a partnership between businessman Friederich Bayer, and Johann Friederich Weskott, a master dyer. This company would specialize in the manufacture of synthetic dyes and was based in Barmen, now part of Wuppertal in Germany. The company grew quickly, exporting dyes all over t…